AU1153902A - Nogo receptor homologs - Google Patents

Nogo receptor homologs

Info

Publication number
AU1153902A
AU1153902A AU1153902A AU1153902A AU1153902A AU 1153902 A AU1153902 A AU 1153902A AU 1153902 A AU1153902 A AU 1153902A AU 1153902 A AU1153902 A AU 1153902A AU 1153902 A AU1153902 A AU 1153902A
Authority
AU
Australia
Prior art keywords
proteins
nogo
methods
compositions
specifically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU1153902A
Other languages
English (en)
Inventor
Stephen M Strittmatter
Richard L Cate
Dinah W Y Sah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Biogen Inc
Original Assignee
Yale University
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Biogen Inc filed Critical Yale University
Publication of AU1153902A publication Critical patent/AU1153902A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU1153902A 2000-10-06 2001-10-06 Nogo receptor homologs Pending AU1153902A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23836100P 2000-10-06 2000-10-06
PCT/US2001/031488 WO2002029059A2 (en) 2000-10-06 2001-10-06 Nogo receptor homologs

Publications (1)

Publication Number Publication Date
AU1153902A true AU1153902A (en) 2002-04-15

Family

ID=22897532

Family Applications (2)

Application Number Title Priority Date Filing Date
AU1153902A Pending AU1153902A (en) 2000-10-06 2001-10-06 Nogo receptor homologs
AU2002211539A Ceased AU2002211539B2 (en) 2000-10-06 2001-10-06 Nogo receptor homologs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002211539A Ceased AU2002211539B2 (en) 2000-10-06 2001-10-06 Nogo receptor homologs

Country Status (12)

Country Link
US (5) US20030124704A1 (cg-RX-API-DMAC7.html)
EP (1) EP1325130B1 (cg-RX-API-DMAC7.html)
JP (2) JP4465148B2 (cg-RX-API-DMAC7.html)
AT (1) ATE458815T1 (cg-RX-API-DMAC7.html)
AU (2) AU1153902A (cg-RX-API-DMAC7.html)
CA (1) CA2424834A1 (cg-RX-API-DMAC7.html)
DE (1) DE60141409D1 (cg-RX-API-DMAC7.html)
DK (1) DK1325130T3 (cg-RX-API-DMAC7.html)
ES (1) ES2341608T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ525422A (cg-RX-API-DMAC7.html)
PT (1) PT1325130E (cg-RX-API-DMAC7.html)
WO (1) WO2002029059A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
WO2002029059A2 (en) * 2000-10-06 2002-04-11 Yale University Nogo receptor homologs
AU2002331180A1 (en) * 2001-08-27 2003-03-10 Novartis Pharma Gmbh Nogo receptor homologues and their use
JP2005519584A (ja) * 2001-10-22 2005-07-07 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
WO2004005510A1 (ja) * 2002-07-05 2004-01-15 Shionogi & Co., Ltd. 新規Nogo受容体様ポリペプチドおよびそのＤＮＡ
CN1681838A (zh) 2002-08-10 2005-10-12 拜奥根Idec马萨诸塞公司 Nogo受体拮抗剂
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
CA2521469A1 (en) 2003-04-04 2004-10-21 University Of Rochester Identification of novel nogo-receptors and methods related thereto
WO2004093893A2 (en) * 2003-04-16 2004-11-04 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
EA008253B1 (ru) * 2003-08-07 2007-04-27 Байоджен Айдек Ма Инк. Антагонисты nogo-рецептора
EP1695061A4 (en) * 2003-12-16 2008-02-20 Childrens Medical Center METHOD OF TREATING NEUROLOGICAL DISORDERS
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
US20080045926A1 (en) * 2004-01-30 2008-02-21 Relton Jane K Treatment of Conditions Involving Dopaminergic Neuronal Degeneration Using Nogo Receptor Antagonists
BRPI0512500A (pt) 2004-06-24 2008-03-11 Biogen Idec Inc tratamento ou condições envolvendo desmielinação
CA2582581A1 (en) * 2004-10-01 2006-05-04 Yale University Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof
US7893032B2 (en) 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
RS53058B (sr) 2005-07-08 2014-04-30 Biogen Idec Ma Inc. Sp35 antitela i njihova primena
CN101248083A (zh) * 2005-08-25 2008-08-20 比奥根艾迪克Ma公司 Nogo受体多肽和多肽片段及其用途
CN103215293B (zh) 2006-01-27 2015-10-28 比奥根Ma公司 Nogo受体拮抗剂
EP2023735A4 (en) * 2006-05-15 2011-05-25 Biogen Idec Inc USE OF ANTAGONISTS OF THE NOGO RECEPTOR 1 (NGR1) TO PROMOTE THE SURVIVAL OF OLIGODENDROCYTES
CA2653456A1 (en) * 2006-05-24 2007-11-29 Richard Daneman Permeability of blood-brain barrier
KR20090082480A (ko) * 2006-11-14 2009-07-30 제넨테크, 인크. 뉴런 재생의 조절인자
US20100047232A1 (en) * 2006-11-14 2010-02-25 Jasvinder Atwal Modulators of neuronal regeneration
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
US20090232794A1 (en) * 2007-12-11 2009-09-17 Marc Tessier-Lavigne Modulators of neuronal regeneration
EP2276500A4 (en) 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES
US20090285803A1 (en) * 2008-05-13 2009-11-19 Jasvinder Atwal ANTI-PirB ANTIBODIES
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
EP2392208B1 (en) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
US9120111B2 (en) 2012-02-24 2015-09-01 Rain Bird Corporation Arc adjustable rotary sprinkler having full-circle operation and automatic matched precipitation
EP2849787A4 (en) 2012-05-14 2016-06-15 Biogen Ma Inc LINGO-2 ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING ENGINE NEURONS
US9156043B2 (en) 2012-07-13 2015-10-13 Rain Bird Corporation Arc adjustable rotary sprinkler with automatic matched precipitation
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
US12343748B2 (en) 2021-03-16 2025-07-01 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method
US12434252B2 (en) 2022-04-20 2025-10-07 Rain Bird Corporation Full-circle and part-circle rotor sprinkler
US12440855B2 (en) 2022-10-27 2025-10-14 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
WO1990005191A1 (en) 1988-11-04 1990-05-17 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
JPH07509002A (ja) 1993-02-11 1995-10-05 エルツィーヒュングスディレクション　オブ　ザ　キャントン　チューリッヒ ニューロトロフィンとミエリン−関連の軸索成長阻害タンパク質に対する抗体との組み合わせが中枢神経系の再生を促進する
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
JP2003521216A (ja) * 1997-08-05 2003-07-15 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９０個のヒト分泌タンパク質
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
AU4682999A (en) * 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
EP1098972B1 (en) 1998-07-22 2010-09-29 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding cdna
MXPA01004598A (es) * 1998-11-06 2002-04-24 Martin E Schwab Secuencias de nucleotidos y proteinas de los genes nogo y metodos basados en estas.
MXPA01005169A (es) 1998-12-01 2002-07-02 Genentech Inc Promocion o inhibicion deangiogenesis y cardiovascularizacion.
ATE353339T1 (de) 1998-12-22 2007-02-15 Genentech Inc Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums
EP1220905A2 (en) 1999-03-08 2002-07-10 Genentech Inc. Composition and methods for the treatment of immune related diseases
KR20030002292A (ko) 1999-03-08 2003-01-08 제넨테크, 인크. 분비 및 막횡단 폴리펩티드 및 이를 코딩하는 핵산
JP2004507202A (ja) 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
AU3632600A (en) 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
WO2001009162A2 (en) 1999-07-30 2001-02-08 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
AU2575901A (en) 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Novel leucine rich repeat-containing molecules and uses therefor
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
HK1051543A1 (zh) * 2000-01-12 2003-08-08 Yale University Nogo受体介导的轴突生长封锁
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
CA2376873A1 (en) 2000-04-18 2001-10-25 Teijin Limited Oxygen concentrating apparatus
WO2002029059A2 (en) * 2000-10-06 2002-04-11 Yale University Nogo receptor homologs
AU2002331180A1 (en) 2001-08-27 2003-03-10 Novartis Pharma Gmbh Nogo receptor homologues and their use
JP2005519584A (ja) 2001-10-22 2005-07-07 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
CN1681838A (zh) 2002-08-10 2005-10-12 拜奥根Idec马萨诸塞公司 Nogo受体拮抗剂

Also Published As

Publication number Publication date
EP1325130B1 (en) 2010-02-24
JP2009100767A (ja) 2009-05-14
DK1325130T3 (da) 2010-05-25
EP1325130A2 (en) 2003-07-09
US20070104713A1 (en) 2007-05-10
US7173118B2 (en) 2007-02-06
ATE458815T1 (de) 2010-03-15
NZ525422A (en) 2006-09-29
PT1325130E (pt) 2010-05-31
US20110129477A1 (en) 2011-06-02
WO2002029059A2 (en) 2002-04-11
US7456255B2 (en) 2008-11-25
CA2424834A1 (en) 2002-04-11
ES2341608T3 (es) 2010-06-23
US20090175850A1 (en) 2009-07-09
DE60141409D1 (de) 2010-04-08
JP2004528809A (ja) 2004-09-24
AU2002211539B2 (en) 2007-01-25
WO2002029059A9 (en) 2003-05-15
US20030124704A1 (en) 2003-07-03
US20050048520A1 (en) 2005-03-03
WO2002029059A3 (en) 2003-01-23
JP4465148B2 (ja) 2010-05-19

Similar Documents

Publication Publication Date Title
AU1153902A (en) Nogo receptor homologs
MXPA02006885A (es) Bloqueo del crecimiento axonal mediado por receptor de nogo.
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
DE60028970D1 (de) An her2 bindende peptidverbindungen
BR0306973A (pt) Anticorpos anti-igf-ir e respectivas aplicações
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
WO2002044320A3 (en) Human elongase genes and uses thereof
WO2004019893A3 (en) Modulators of angiogenesis
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
DK0811068T3 (da) Humane DNase I varianter
WO2002062996A1 (en) Novel physiologically active peptide and use thereof
WO2002070560A3 (en) Nuclear hormone receptor ligand binding domain
WO2002000834A3 (fr) Nouveau polypeptide, proteine phosphatase humaine 9.68, et polynucleotide codant ce polypeptide
MXPA03005564A (es) Nueva proteina que contiene repeticiones ricas en leucina de humano que es expresada predominantemente en medula osea, hlrrbm1.
TW200635950A (en) Specific binding agents of human angiopoietin-2
WO2002046380A3 (en) Protein kinase
MX9706429A (es) Variantes de dnasa i humana.